12 Months, 12 Solutions – Countdown to the EU Falsified Medicines Directive

October Pharma-Security Feature: NFC-Label for digital tamper evidence

Treatment by self-medication with autoinjectors: a growing trend. For patients, the ease and safety of handling are particularly important. For pharmaceutical manufacturers, the protection of patients against fake medicines and security of the supply chain are crucial. The EU FMD, besides serialization, requires tamper protection of secondary packaging, however without considering first-opening indication for injection devices. That is exactly what the NFC-Label for autoinjectors is offering.

It is both user-friendly and safe: The NFC-Label for digital tamper evidence wraps around the autoinjector including the cap and has an integrated NFC chip that can be read very easily via a smartphone app. Before opening the cap for the first time, the patient checks if the product is an original and receives respective confirmation. After opening the cap and label, and subsequently reading the NFC chip once more, a warning will appear on the smartphone that indicates whether the product has previously been opened and may have been tampered with. Thus, patients are able to easily and quickly check the intactness of their injection aids anywhere, anytime—and above all, can be certain to have received a safe medicine.

The new NFC-Label and corresponding smartphone app make it possible for users to unequivocally verify if the product is still in its originally sealed condition or has been opened before.

To optimally support patients during self-medication, pharmaceutical manufacturers are able to include additional interactive applications in the NFC chip such as product information, demo videos or special apps. Additionally integrated geo-tracking makes it possible to detect potential gray market activities in local markets.

The digital NFC-Label for autoinjectors can easily be adapted to existing label designs and does not affect the normal application by the patient. For pharmaceutical manufacturers, Schreiner MediPharm’s smart label solution enhances product and patient safety, supports the integrity of the supply chain—and closes a potential risk gap in the EU Falsified Medicines Directive.

In our blog series “12 Months, 12 Solutions: The Countdown to the EU Falsified Medicines Directive” over the next twelve months, we will present twelve selected security features that can be used to make medicinal packaging counterfeit-proof.

For more information on Schreiner MediPharm and our innovative Solutions for the Pharmaceutical and Medical Device Industry, please visit: www.schreiner-medipharm.com

The last comment needs to be approved.
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

This post is also available in: German